National Comprehensive Cancer Network
- NCCN
Guidelines®- End User License Agreement
- NCCN Guidelines for
Treatment of Cancer by Site- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Anal Carcinoma
- Basal and Squamous Cell Skin Cancers
- Bladder Cancer
- Bone Cancer
- Breast Cancer
- Central Nervous System Cancers
- Cervical Cancer
- Chronic Myelogenous Leukemia
- Colon Cancer
- Dermatofibrosarcoma Protuberans
- Esophageal and Esophagogastric Junction Cancers
- Gastric Cancer
- NCCN Guidelines for Detection,
Prevention, & Risk Reduction - NCCN Guidelines for
Supportive Care - NCCN Guidelines for
Age Related Recommendations - NCCN Guidelines for Patients®
- International Adaptations & Translations
- NCCN Pocket Guidelines
- NCCN Disclosure Policies &
Potential Conflicts of Interest - Licensing and Permissions
- Stay up-to-date with
NCCN Flash Updates™ - NCCN Guidelines Apps
- NCCN
Compendia- End User License Agreement
- NCCN Compendium®
- NCCN Biomarkers Compendium™
- Subscribe to the NCCN Compendia
- Licensing and Permissions
- Subscriptions
& Products- NCCN Compendium
- NCCN Biomarkers Compendium
- NCCN Templates
- Combination Subscriptions
- NCCN Flash Updates™
- NCCN Flash Updates™ Coupons
- NCCN Trends™ Surveys & Data
- NCCN Academy Video Modules
- NCCN eBulletin Newsletter
- NCCN Health Information Technology Licensees
- JNCCN — Journal of the National Comprehensive Cancer Network
- Advertising Opportunities
- NCCN Online Catalog
- Clinical & Business
Resources- Members Only
- NCCN Corporate Council
- NCCN Academy
- NCCN Insights: Analytics, Research & Consulting
- NCCN Resource Tool: REMS
- NCCN Collaboration with the National Business Group on Health
- NCCN Virtual Reimbursement Resource Room
- NCCN Health Information Technology Licensees
- NCCN Oncology Policy Program White Papers
- NCCN Oncology Research Program (ORP)
- ORP Recent News
- NCCN ORP Affiliate Research Project
- ORP Scientific Publications
- ORP Investigator Steering Committee
- ORP Testimonials
- Clinical Trials at NCCN Member Institutions
- Find ORP Funded Clinical Trials at NCCN Member Institutions
- NCCN Specialized Imaging Research Consortium™ (SIRC)
- NCCN ORP Disclosure Policy
- NCCN ORP for Industry
- NCCN Informed Consent Language Database
- NCCN Content Policies
- Patient
Resources- NCCN Guidelines for Patients®
- NCCN Website for Patients and
Caregivers - NCCN.com - Find an NCCN Member Institution
- Find an NCCN Cancer Center Near You
- Information on Patient Assistance & Reimbursement Help
- NCCN Virtual Reimbursement Resource Room Guide
- Find Clinical Trials
- NCCN Foundation
- Donate to the NCCN Foundation
About NCCN
NCCN Updates: Guidelines, Drugs & Biologics, Order Templates
The NCCN Clinical Practice Guidelines in Oncology™ for Uterine Neoplasms have been updated to v.1.2010. For patients with recurrent, metastatic, or high-risk endometrial carcinoma, systemic therapy with ixabepilone as a single agent was added as a second line option. This recommendation is listed as Category 2B.
The NCCN Clinical Practice Guidelines in Oncology™ for Cervical Cancer have also been updated and published by NCCN as v.1.2010.
For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology™, the NCCN Drugs & Biologics Compendium™, and the NCCN Chemotherapy Order Templates™ please visit NCCN.org.
| Quick Links |
|
|
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved